Fate Therapeutics Inc (FATE)
2.07
-0.15
(-6.76%)
USD |
NASDAQ |
Nov 21, 16:00
2.07
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Enterprise Value: -61.16M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -61.16M |
| November 20, 2024 | -44.07M |
| November 19, 2024 | -48.63M |
| November 18, 2024 | -38.38M |
| November 15, 2024 | -66.85M |
| November 14, 2024 | -60.02M |
| November 13, 2024 | -49.77M |
| November 12, 2024 | -25.85M |
| November 11, 2024 | -5.351M |
| November 08, 2024 | -21.30M |
| November 07, 2024 | -6.490M |
| November 06, 2024 | 20.85M |
| November 05, 2024 | 8.317M |
| November 04, 2024 | 17.40M |
| November 01, 2024 | -20.18M |
| October 31, 2024 | -27.01M |
| October 30, 2024 | -13.35M |
| October 29, 2024 | 12.85M |
| October 28, 2024 | 29.93M |
| October 25, 2024 | 4.875M |
| October 24, 2024 | 23.10M |
| October 23, 2024 | 48.15M |
| October 22, 2024 | 66.37M |
| October 21, 2024 | 61.82M |
| October 18, 2024 | 70.93M |
| Date | Value |
|---|---|
| October 17, 2024 | 69.79M |
| October 16, 2024 | 68.65M |
| October 15, 2024 | 50.43M |
| October 14, 2024 | 50.43M |
| October 11, 2024 | 54.98M |
| October 10, 2024 | 37.90M |
| October 09, 2024 | 45.87M |
| October 08, 2024 | 52.71M |
| October 07, 2024 | 50.43M |
| October 04, 2024 | 69.79M |
| October 03, 2024 | 58.40M |
| October 02, 2024 | 68.65M |
| October 01, 2024 | 84.59M |
| September 30, 2024 | 101.68M |
| September 27, 2024 | 101.67M |
| September 26, 2024 | 93.70M |
| September 25, 2024 | 88.00M |
| September 24, 2024 | 88.00M |
| September 23, 2024 | 109.64M |
| September 20, 2024 | 135.83M |
| September 19, 2024 | 150.64M |
| September 18, 2024 | 136.97M |
| September 17, 2024 | 150.64M |
| September 16, 2024 | 146.08M |
| September 13, 2024 | 152.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-187.06M
Minimum
Oct 27 2023
10.42B
Maximum
Jan 14 2021
2.385B
Average
1.695B
Median
Jun 09 2022
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
| Oragenics Inc | 2.273M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -47.68M |
| Revenue (Quarterly) | 3.074M |
| Total Expenses (Quarterly) | 55.45M |
| EPS Diluted (Quarterly) | -0.40 |
| Profit Margin (Quarterly) | -1.55K% |
| Earnings Yield | -79.71% |
| Normalized Earnings Yield | -79.71 |